Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bogni

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
The International Journal of Biological Markers|January 1, 1992
Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathologyG Saccani Jotti, M Fontanesi, E Bombardieri, et al.
Tumori|March 1, 1997
Radiopharmaceuticals for breast cancer imagingL Maffioli, E Seregni, A Chiti, et al.
The International Journal of Biological Markers|April 1, 1994
Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trialE Bombardieri, E Seregni, A Bogni, et al.
International Journal of Oncology|May 12, 2011
Reliability of immunoradiometric assays for sex-hormone binding globulin, androstenedione, 17-Beta estradiol and tumor-markers cea and cb15.3 to assess the biological response of megestrol-acetate treatment in patients with advanced breast-cancerC Botti, A Bogni, E Seregni, et al.
Anticancer Research|July 23, 1998
A simple and semi-automated system for increasing the recovery of aqueous [18F] fluoride from targetC Pascali, A Bogni, D Decise, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastasesE Bombardieri, M Pizzichetta, P Veronesi, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|February 20, 2010
Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary resultsE Seregni, M Maccauro, A Coliva, et al.
European Journal of Nuclear Medicine|February 21, 1998
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucoseC Chiesa, V De Sanctis, F Crippa, et al.
Oncology Reports|May 21, 2011
Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancerG Vicario, L Celio, E Bajetta, et al.
Oncology Reports|May 20, 2011
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC)E Seregni, P Foa, A Bogni, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
The International Journal of Biological Markers|January 1, 1992
Preliminary study on oncogene product immunohistochemistry (c-erbB-2, c-myc, ras p21, EGFR) in breast pathologyG Saccani Jotti, M Fontanesi, E Bombardieri, et al.
Tumori|March 1, 1997
Radiopharmaceuticals for breast cancer imagingL Maffioli, E Seregni, A Chiti, et al.
The International Journal of Biological Markers|April 1, 1994
Evaluation of cytokeratin 19 serum fragments (CYFRA 21-1) in patients with lung cancer: results of a multicenter trialE Bombardieri, E Seregni, A Bogni, et al.
International Journal of Oncology|May 12, 2011
Reliability of immunoradiometric assays for sex-hormone binding globulin, androstenedione, 17-Beta estradiol and tumor-markers cea and cb15.3 to assess the biological response of megestrol-acetate treatment in patients with advanced breast-cancerC Botti, A Bogni, E Seregni, et al.
Anticancer Research|July 23, 1998
A simple and semi-automated system for increasing the recovery of aqueous [18F] fluoride from targetC Pascali, A Bogni, D Decise, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1992
CA 15.3 determination in patients with breast cancer: clinical utility for the detection of distant metastasesE Bombardieri, M Pizzichetta, P Veronesi, et al.
The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of|February 20, 2010
Treatment with tandem [(90)Y]DOTA-TATE and [(177)Lu] DOTA-TATE of neuroendocrine tumors refractory to conventional therapy: preliminary resultsE Seregni, M Maccauro, A Coliva, et al.
European Journal of Nuclear Medicine|February 21, 1998
Radiation dose to technicians per nuclear medicine procedure: comparison between technetium-99m, gallium-67, and iodine-131 radiotracers and fluorine-18 fluorodeoxyglucoseC Chiesa, V De Sanctis, F Crippa, et al.
Oncology Reports|May 21, 2011
Clinical and endocrine effects of megestrol-acetate in women with pretreated advanced breast-cancerG Vicario, L Celio, E Bajetta, et al.
Oncology Reports|May 20, 2011
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC)E Seregni, P Foa, A Bogni, et al.
Pageof 5